BDBM644607 Preparation of 20,20,22-trimethyl-4-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-10λ6-thia-1,3,9,13,14-pentaazatetracyclo[16.2.1.111,14.02,7]docosa-2,4,6,11(22),12-pentaene-8,10,10-trione (Compound 18) and 12,20,20-trimethyl-4-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-10λ6-thia-1,3,9,13,14-pentaazatetracyclo[16.2.1.111,14.02,7]docosa-2,4,6,11(22),12-pentaene-8,10,10-trione ::US11866450, Compound 19

SMILES Cc1nn2CCCC3CN(c4nc(ccc4C(=O)NS(=O)(=O)c1c2)-n1ccc(OCCC2(CC2)C(F)(F)F)n1)C(C)(C)C3

InChI Key InChIKey=FYFXHOIIPAMYGO-UHFFFAOYSA-N

Data  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 644607   

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644607(US11866450, Compound 19 | Preparation of 20,20,22-...)
Affinity DataEC50:  2.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
Go to US Patent